Background-␤-Blockers are known to reduce total mortality and sudden death in survivors of recent myocardial infarction. The effects of these agents in patients at high risk for sudden death with remote infarction are not clear. Methods and Results-We analyzed the effect of ␤-blockers on outcomes in 2096 patients with coronary artery disease, ejection fraction Յ40%, and spontaneous nonsustained ventricular tachycardia enrolled in the Multicenter UnSustained Tachycardia Trial (MUSTT). Forty-five percent of 702 patients with inducible sustained ventricular tachyarrhythmia and 35% of 1394 patients without inducible tachycardia were discharged from hospital receiving ␤-blockers. Patients treated with ␤-blockers were younger and had higher ejection fractions, higher rates of recent angina, and more recent infarction. ␤-Blockers were associated with decreased total mortality for the entire study population (5-year mortality 50% with ␤-blockers versus 66% without ␤-blockers; adjusted Pϭ0.0001). The mortality benefit associated with ␤-blockers was present in patients with and without inducible tachycardia, except those treated with implantable defibrillators. There was no significant effect of ␤-blocker therapy on the rate of arrhythmic death or cardiac arrest (adjusted Pϭ0.2344).
␤ -Blocking agents reduce total mortality by 25% to 40% in patients with a recent myocardial infarction (MI). [1] [2] [3] [4] [5] [6] [7] [8] Pooled data from 18 000 patients show that ␤-blockers reduce sudden cardiac death by 32% to 50%. 6 These trials examined the effects of ␤-blockers when initiated early after an index infarction, with follow-up ranging from 3 to 72 months. In addition, ␤-blockers have been linked with a reduced risk of death for survivors of ventricular fibrillation and tachycardia. 9, 10 The Multicenter UnSustained Tachycardia Trial (MUSTT) was designed to test the effectiveness of electrophysiologically guided antiarrhythmic therapy in reducing the risk of arrhythmic death, cardiac arrest, and total mortality in patients with coronary artery disease, ejection fraction Յ40%, and spontaneous nonsustained ventricular tachycardia (VT). 11 The use of ␤-blockers was strongly encouraged in all patients. Patients were enrolled in the MUSTT trial a median of 39 months after their most recent acute MI, with 17% enrolled within 1 month of an acute MI. The potential benefits of ␤-blocking agents at a time this far removed from infarction are not clear, nor have the effects of these agents been evaluated in a population at high risk for arrhythmic events, such as those enrolled in this trial.
In the present analysis, we evaluate the impact of ␤-blockers on total mortality and arrhythmic events (arrhythmic death or resuscitated cardiac arrest) in patients enrolled in the MUSTT trial.
Methods Population
Details of the MUSTT study protocol have been described previously. 11 MUSTT was a prospective, randomized, controlled trial; patients who had coronary artery disease, left ventricular ejection fraction Յ40%, and asymptomatic nonsustained VT (defined as Ն3 consecutive premature ventricular contractions with a rate Ͼ100 bpm) were candidates for enrollment. Eligible patients underwent a baseline electrophysiological study in the absence of antiarrhythmic drugs with a standardized stimulation protocol. Patients with sustained monomorphic VT (induced by 1, 2, or 3 extrastimuli) and patients with sustained polymorphic VT including ventricular fibrillation and flutter (induced by 1 or 2 extrastimuli) were randomly assigned in equal proportions to antiarrhythmic therapy guided by serial electrophysiological testing or no antiarrhythmic therapy. The status of patients in whom no sustained tachyarrhythmia was induced at the baseline study and who received no antiarrhythmic therapy was recorded in a registry. 12 In the main trial and in the registry, arrhythmic death or nonfatal cardiac arrest was reported as the primary end point and all-cause mortality as a key secondary end point.
Patients assigned to electrophysiologically guided therapy underwent serial drug testing with antiarrhythmic drugs. If no drug regimen could be found that rendered the tachyarrhythmia noninducible, the investigator could discharge the patient with a prescription for a drug that was associated with hemodynamic stability during induced tachycardia. No empirical antiarrhythmic drug therapy was used. Implantation of a cardioverter/defibrillator (ICD) could be recommended after Ն1 unsuccessful drug trial. Patients who declined defibrillator implantation were discharged receiving no antiarrhythmic drugs.
Of the 2202 patients enrolled at 85 sites in the United States and Canada between November 1, 1990 , and October 31, 1996 , 2096 (702 randomized patients and 1394 registry patients) were used for the present analysis. Excluded from the analysis were 101 registry patients who had inducible VT but either refused randomization (63 patients) or had nonreproducible induction of VT (38 patients). Also excluded were 5 patients (2 randomized patients and 3 registry patients) whose ␤-blocker status at hospital discharge was unknown. For the analyses in the present report, patients were considered to be in the group receiving ␤-blocking therapy if they were taking ␤-blockers at the time of discharge after enrollment. Patients discharged taking sotalol (nϭ33 randomized patients, and 3 registry patients given sotalol for atrial fibrillation) were considered in the group of patients taking ␤-blocking agents for the purpose of the present analysis. We also performed the analyses excluding patients receiving sotalol from the ␤-blocker group. Propafenone was not considered a ␤-blocker. Patients who did not survive to hospital discharge were included in the analysis if ␤-blocker use was known at the time of death.
Statistical Analysis
The distributions of baseline characteristics were summarized with medians and 25th and 75th percentiles for continuous variables and percentages for categorical variables. Group differences in baseline characteristics, medications, and ECG characteristics were assessed with the Wilcoxon rank-sum test (for continuous variables) and the 2 test (for categorical variables). All tests of significance were 2-tailed. Cumulative event rates and survival curves were calculated by the Kaplan-Meier method, and outcome differences of patients treated with ␤-blockers versus those not treated were assessed with the log-rank test. 13 In addition, covariate-adjusted analyses of the effect of ␤-blockers on outcomes were performed with the Cox proportional hazards model. 14 Covariates included in these analyses were induction of randomizable VT, age, sex, race, ejection fraction, duration (in beats) of the longest episode of nonsustained VT, number of vessels with Ն75% stenosis, history of MI, prior thrombolytic therapy, left bundle-branch block, intraventricular conduction delays, use of digitalis at baseline, prior bypass surgery or angioplasty, or symptoms of angina within 6 weeks before enrollment. Hazard ratios and 95% confidence intervals (CI) were calculated with the Cox proportional hazards model.
Results
Of the 2096 patients in the present analysis, 799 (38%) received ␤-blockers at the time of hospital discharge after enrollment in the trial (Table 1) . Of 702 patients with inducible sustained VT, 314 (45%) received ␤-blockers. At last follow-up, 67% of these patients were still taking ␤-blockers. Of the patients with inducible tachycardia who were not treated with specific antiarrhythmic therapy, 51% received ␤-blockers versus 37% (65 of 177) of ICD-treated patients versus 39% (62 of 159) of patients treated with pharmacological antiarrhythmic therapy. A total of 7 patients randomized to electrophysiologically guided therapy were discharged taking ␤-blocking agents in addition to amiodarone, sotalol, or propafenone. Of the 1394 registry patients, 485 (35%) were taking ␤-blockers at the time of hospital discharge, and 65% of this group of patients were still taking ␤-blockers at last follow-up.
Patients treated with ␤-blockers were younger and had higher ejection fractions, higher rates of recent angina, and more recent infarction ( Table 1 ). This patient group was more likely to have received thrombolytic therapy and to have previously undergone angioplasty. A greater percentage of patients treated with ␤-blockers were in New York Heart Association (NYHA) class I and had lower rates of congestive heart failure than the patients not taking ␤-blockers at discharge. All patients discharged taking ␤-blockers had lower rates of digitalis and ACE inhibitor use at baseline. Registry patients discharged taking ␤-blockers also had a lower rate of calcium channel blocker use at baseline ( Table  2) . A comparison of baseline ECG characteristics showed that patients receiving ␤-blockers at discharge had lower rates of left ventricular hypertrophy, left bundle-branch block, and intraventricular conduction delays than patients not taking ␤-blockers (Table 3 ).
The 2-and 5-year total mortality rates of 16% and 34% for patients receiving ␤-blockers at discharge were significantly lower than the total mortality rates of 27% and 50% for patients not receiving ␤-blockers at discharge (unadjusted Pϭ0.0001 and covariate-adjusted Pϭ0.0001; Figure 1 ; Table  4 ). The mortality benefit of ␤-blockers was consistent across the spectrum of study patients (adjusted hazard ratios from 0.63 to 0.72), except for randomized ICD-treated patients ( Table 4 ). The latter group of 177 patients (65 receiving ␤-blockers and 112 not taking ␤-blockers) demonstrated a 5-year mortality rate of 23% in patients taking ␤-blockers and 27% in those who were not.
In contrast to the beneficial effect of ␤-blockers on total mortality, there was no significant benefit of ␤-blocker therapy on the primary end point of arrhythmic death or cardiac arrest, after adjustment for the previously mentioned differences in baseline factors (Figure 2 ; Table 4 ). The adjusted hazard ratios, however, did show a trend toward a benefit of ␤-blockers in decreasing arrhythmic events (adjusted hazard ratios from 0.81 to 0.88) for all subgroups except the randomized ICD-treated patients.
When we performed the above analyses excluding patients from the ␤-blocker group who were receiving sotalol, there was no significant difference in the results.
Discussion
The present study demonstrates that ␤-blocker use is associated with improved survival in all subgroups of patients enrolled in the MUSTT trial, with the exception of those treated with ICDs. This benefit extended to patients with and without inducible ventricular tachyarrhythmias. Although there are abundant data substantiating the beneficial effects of
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␤-blockers on survival in patients with recent MI, our results extend these benefits to a high-risk subgroup of patients, the majority of whom had a remote infarction. The median time from infarction to enrollment was 39 months, which suggests that the beneficial effects of ␤-blockers persist for long periods after MI. The protective mechanism of ␤-blockers is unclear but likely relates to a combination of their anti-ischemic, antiarrhythmic, antihypertensive, and antiadrenergic properties.
In the European Myocardial Infarction Amiodarone Trial (EMIAT) and the Canadian Amiodarone Myocardial Infarc-tion Arrhythmia Trial (CAMIAT), high-risk patients with recent MI were randomly assigned to either amiodarone or placebo. 15, 16 In both of these trials, amiodarone therapy appeared to have a greater effect on reducing mortality in those patients taking ␤-blocking agents. The results of these trials were published after enrollment in the MUSTT trial had been completed.
␤-Blockers have also been shown to reduce mortality by 26% to 65% in patients with symptomatic heart failure. [17] [18] [19] [20] [21] [22] The results of the major heart failure trials were not available at the onset of the MUSTT trial; therefore, the significant benefit of ␤-blocker therapy in patients with congestive heart failure was not established. This is the likely cause of the low overall use of ␤-blockers in this trial. In the MUSTT trial, 25% of patients were categorized in NYHA class III and 39% in NYHA class II. ICD therapy has been shown to provide a significant mortality benefit in patients who have survived cardiac arrest, in those with depressed left ventricular function secondary to coronary artery disease with spontaneous nonsustained VT and inducible sustained VT that is not suppressed by pharmacological antiarrhythmic therapy. 11, 23, 24 In addition, a recent trial demonstrated that ICDs can reduce mortality in patients with prior MI who have an ejection fraction Յ30%, regardless of the presence or absence of documented spontaneous nonsustained VT. 25 In two recent trials comparing ICDs with empiric pharmacological antiarrhythmic therapy for primary and secondary prevention of sudden death, ICD therapy demonstrated a significant mortality benefit in patients at high risk for death or recurrent arrhythmias. 23, 24 However, in those trials, patients randomly assigned to ICD therapy were also given ␤-blockers significantly more often than patients receiving pharmacological antiarrhythmic treatment, which has led some to question the contribution of ␤-blockers to the observed superiority of ICD therapy. The benefit of ICDs in the MADIT-II (Multicenter Automatic Defibrillator Implantation Trial II) study was observed even though 70% of patients in both the ICD and control arms received ␤-blocker therapy. 25 Of note, MUSTT patients discharged with ICDs received ␤-blockers significantly less often than patients randomized to no antiarrhythmic therapy. Thus, the favorable effect of ICD therapy on survival in the MUSTT trial cannot be explained by bias in ␤-blocker usage, as occurred in the other trials.
Our findings are consistent with the ␤-blocker substudy of the AVID (Antiarrhythmics Versus Implantable Defibrillators) trial, in which ␤-blocker use was not associated with improved survival in patients with ventricular fibrillation or symptomatic VT treated with amiodarone or ICD therapy. 26 ␤-Blocker use in AVID patients was associated with an independent mortality reduction in eligible, nonrandomized patients who were not treated with amiodarone or ICD therapy. However, the AVID data contrasted with those obtained from EMIAT and CAMIAT, in which the benefit of ␤-blockers appeared to be more significant in patients with elevated resting heart rates. 15, 16 We did not collect information on the resting heart at entry into the present study. In the MUSTT trial, there was a trend toward fewer arrhythmic events and improved survival in those treated with antiarrhythmic drugs in combination with ␤-blocker therapy compared with antiarrhythmic therapy alone. This trend was not observed in patients who received ICD therapy. This is likely a reflection of the significant impact of ICD therapy on sudden cardiac death and the difficulty in further decreasing event rates. 
Study Limitations
Administration of ␤-blocker therapy was left to the discretion of the referring physicians and therefore was not randomized. The effects of ␤-blockers in patients who received pharmacological antiarrhythmic therapy may also be obscured be-cause several of these agents possess some ␤-blocker activity. The small number of patients given individual antiarrhythmic drugs also limits the power to detect differences of the effect of ␤-blockers depending on the particular antiarrhythmic drug used. BB indicates ␤-blocker; AA, antiarrhythmic. *Untreated refers to patients who were discharged receiving no antiarrhythmic medication and who did not receive an ICD within 90 days of enrollment.
†Adjusted for presence of randomizable VT, age, ejection fraction, race, sex, longest episode of nonsustained VT, prior MI, prior CABG surgery, prior percutaneous coronary intervention (PCI), number of diseased vessels (Ն75% stenosis), angina symptoms within 6 weeks of enrollment, prior thrombolytic therapy, left bundle-branch block, intraventricular conduction delays, and digitalis use at baseline.
Figure 2.
Rates of arrhythmic death or cardiac arrest related to use of ␤-blockers or lack of ␤-blockers over course of trial. Unadjusted event rates were significantly lower in patients treated with ␤-blockers. After adjustment for covariates noted in Figure 1 , event rates were not significantly lower in patients treated with ␤-blockers.
